Time-of-Day as a Regulatory Variable in Cancer Therapy: Empirical Support for the R0–R2 Layers of the NOAH6 Hierarchical Model Based on Immunochemotherapy Timing in ES-SCLC

The NOAH6 model conceptualizes carcinogenesis and therapeutic response as emergent properties of a hierarchically organized regulatory system rather than as isolated genetic or pharmacological phenomena. While previous works within the NOAH6 framework have provided empirical support for higher (R3–R4) and lower (R5) layers, direct clinical evidence for the foundational temporal and neuroendocrine layers (R0–R2) has been limited. This paper analyzes the retrospective cohort study by Huang et al. (Cancer, 2025), which demonstrates that the time-of-day of immunochemotherapy administration (ToDA) in extensivestage small cell lung cancer (ES-SCLC) is independently associated with objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Using a rigorously controlled design—including multivariate Cox regression and propensity score matching—the study identifies treatment initiation before 15:00 as a statistically significant predictor of superior outcomes. We show that these findings provide the strongest empirical support to date for the R0 (temporal/circadian framework) and R2 (central neuroendocrine executive regulation) layers of the NOAH6 hierarchy. The results indicate that therapeutic efficacy is not atemporal but is modulated by the systemic temporal state of the organism. This supports the NOAH6 thesis that cancer therapy outcomes are emergent properties of hierarchical regulatory coherence rather than intrinsic properties of drugs or tumors alone.